Intraday €0.025 move: 6L9.F ViewRay, Inc. (XETRA) high-volume mover 17 Feb 2026

The 6L9.F stock jumped to €0.025 intraday on XETRA on 17 Feb 2026 after a sharp volume spike. We saw volume 3,500 shares, a relative volume of 12.54, and a one-month move printed as +2400.00% in the data feed. This intraday action puts ViewRay, Inc. (6L9.F) on scanners as a high-volume mover in the Healthcare – Medical Devices group. Traders should note the jump occurred from an open of €0.001 and a prior close of €0.001, so the move reflects thin-market volatility as well as increased attention.

6L9.F stock intraday snapshot

Price action: 6L9.F stock traded from a day low of €0.001 to a day high of €0.025 on heavy intraday flow. Volume: reported 3,500 shares versus an average volume of 279 shares, signalling a large intraday volume multiple. Market cap: ViewRay shows a market cap near €207,228,256.00 based on 8,289,130,240 shares outstanding. Timing: this is an intraday report for 17 Feb 2026 on XETRA.

6L9.F stock news and drivers

Catalyst: public filings and investor attention often drive moves in low-price, low-liquidity names like ViewRay. Correlation: ViewRay, Inc. (6L9.F) operates MRI-guided radiation therapy systems. Supply-demand: thin trading depth means modest orders can swing prices sharply. Sources: company details and product overview are on the ViewRay website and recent coverage is available from Reuters ViewRay investor and Reuters on ViewRay.

6L9.F stock technical and volume analysis

Momentum: the one-month change shows +2400.00%, but three-month and six-month moves are deeply negative, reflecting prior drawdowns. Moving averages: 50-day average €0.32, 200-day average €2.72, both well above the current price, indicating long-term downtrend pressure. Liquidity: the relVolume of 12.54 signals a temporary surge in interest, not sustained market liquidity. Risk: very wide intraday spreads and low depth raise execution risk for larger orders.

6L9.F stock fundamentals and valuation

Profitability: ViewRay reports EPS -0.55 and a negative P/E ratio, so earnings remain in deficit. Valuation ratios: price-to-sales 2.40, price-to-book 0.07, EV/sales 1.92. Balance sheet: cash per share 0.75, current ratio 2.36, and debt-to-equity 1.05. Operational metrics: R&D to revenue stands at 31.73%, which supports product development but pressures margins. These figures show a capital-intensive medical-device firm still working toward consistent profitability.

Meyka AI rates 6L9.F with a score out of 100

Meyka AI rates 6L9.F with a score of 61.29 / 100, grade B, suggestion HOLD. This grade factors S&P 500 benchmark comparison, sector performance, industry peers, financial growth, key metrics, forecasts, analyst consensus, and fundamental growth. This is a model-derived snapshot and not personalised investment advice.

6L9.F stock trading strategy and risks

Strategy: for intraday traders, use tight size limits and limit orders due to low depth. Swing traders should wait for confirmation above the 50-day average €0.32 or clear improvements in volume profile. Risks: share price history shows a year high €4.60 and a year low €0.0005, underlining extreme volatility. Sector context: Healthcare device peers show steadier volumes; ViewRay’s volatility is above sector norms, increasing both opportunity and downside.

Final Thoughts

Key takeaways: 6L9.F stock moved to €0.025 intraday on 17 Feb 2026 on a volume burst of 3,500 shares. Fundamentals show negative EPS -0.55, price-to-book 0.07, and cash per share €0.75, so the company has liquidity but remains unprofitable. Meyka AI’s forecast model projects a base-case price target of €0.05, implying a potential upside of +100.00% versus the current €0.025. A bull scenario at €0.15 implies +500.00%, while a downside case at €0.01 implies -60.00%. Forecasts are model-based projections and not guarantees. Traders should treat intraday moves in ViewRay as high-risk, size positions carefully, and monitor volume and corporate news closely. For a company overview, visit the official ViewRay investor page and our Meyka stock page for live data and alerts Meyka stock page.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.